In this small, randomized, double-blind, Phase II, multicenter, placebo-controlled, exploratory study, researchers investigated whether monotherapy with Orencia, administered for six months and then withdrawn, was more effective than
In the suit, Elan claimed that Abraxis infringed upon two of its patents 5,834,025 and 5,399,363, asserting Abraxane uses technology protected by Elan-owned patents. Elan later withdrew its
Mr Webster will succeed former CFO Thomas Hess, who has resigned to pursue another business opportunity. Most recently, Mr Webster has served as managing director of investment banking
GlaxoSmithKline’s Requip XL is said to be the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson’s disease. The product should be available in pharmacies in
The acquisition is based on the offer price of 135 pence in cash for each ClinPhone share. The offer price represents a premium of 86% to the ClinPhone
Mr Liao joined the company in March 2008, and had served in various capacities before being appointed to the role of CFO on May 7, 2008. Yukun Zhang,
In this study of heavily pretreated patients, 83 were eligible for response evaluation. An objective response was observed in 29% of patients, with 6% achieving a complete response
NuView Radiopharmaceuticals will act as exclusive agent for Positron’s brand of Pet, Spect and automated dose dispensing systems. Paul Crowe, CEO of NuView, said: “We’re very pleased to
The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as
The results of this 500 patient study, which is taking place at specialist and general centres in the US and Canada, are expected in the first quarter of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.